1.
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2008; 18 (3): 176-178
en Inglés
| IMEMR
| ID: emr-100294
RESUMEN
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response